Skip to main content

Anticholinergic / Antimuscarinic Agents

Anticholinergic medications (antimuscarinics) are a cornerstone of urologic pharmacotherapy, primarily for overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (NLUTD).[1][2] They block muscarinic receptors (M2 and M3) in the detrusor muscle, inhibiting involuntary contractions, increasing bladder capacity, and reducing urgency and frequency.

The class has six FDA-approved agents[40] with broadly similar efficacy and different tolerability and CNS penetration; comparative long-term dementia risk across agents remains uncertain.[2][14] The 2024 AUA/SUFU guideline recommends offering either an antimuscarinic or a β3-agonist for idiopathic OAB .[14] Its discussion cites the 2022 SUFU white paper, which advises that a β3-agonist trial is typically preferred before an antimuscarinic when drug therapy is indicated.[11][14]

Mechanism of Action​

  • M3 receptors produce direct detrusor smooth muscle contraction via extracellular calcium entry (L-type channels) and Rho kinase activation
  • M2 receptors (more numerous) facilitate M3-mediated contractions and can reverse β-adrenoceptor-mediated relaxation[3][4]
  • Antagonism of M3 leads to inhibition of detrusor contraction, which increases bladder capacity and reduces urgency
  • Off-target effects at other muscarinic receptor populations produce the class side-effect profile

Receptor selectivity​

  • M3-selective: darifenacin, solifenacin
  • Non-selective (M1–M5): oxybutynin, tolterodine, trospium, fesoterodine
  • Non-selective agents cause broader side effects (salivary glands, CNS, heart, gut)[3][5]

CNS penetration — the mechanism behind dementia risk​

  • High CNS penetration: oxybutynin (lipophilic, non-selective)
  • Low CNS penetration in a single-dose rat study: darifenacin and 5-HMT (fesoterodine's active metabolite); solifenacin and tolterodine showed significant CNS penetration.[49]
  • Minimal CNS penetration: trospium (quaternary amine; poorly crosses BBB)[3][6]

Blood-brain-barrier properties inform drug selection.[14]

FDA-Approved Agents​

Six anticholinergic medications are FDA-approved for OAB in the United States.[2]

AgentReceptor selectivityCNS penetrationTypical doseDistinguishing feature
Oxybutynin (IR, ER, TD patch, topical gel)Non-selectiveHighIR: 5 mg TID; ER: 5–30 mg daily; patch delivers 3.9 mg/day, changed twice weekly[24]Oldest; most extensive evidence; highest dementia concern; transdermal avoids first-pass metabolism and reduces systemic side effects
Tolterodine (IR, ER)Non-selectiveModerateIR: 2 mg BID (1 mg BID with significant renal/hepatic impairment or a potent CYP3A4 inhibitor); ER: 4 mg daily (2 mg with CrCl 10–30 mL/min, Child-Pugh A/B, or a potent CYP3A4 inhibitor; not recommended with CrCl <10 mL/min or Child-Pugh C)[36][43]Less dry mouth than IR oxybutynin[7]
FesoterodineNon-selective (prodrug → active 5-HMT)Low in preclinical studies (5-HMT)[11]Start 4 mg daily; increase to 8 mg if tolerated; maximum 4 mg with CrCl <30 mL/min or a strong CYP3A4 inhibitor[41]Prodrug converted to 5-HMT, tolterodine's active metabolite; flexible dosing; not recommended with clinically significant bladder outlet obstruction[7][41]
SolifenacinM3-selectiveModerateStart 5 mg daily; increase to 10 mg if tolerated, but do not exceed 5 mg with CrCl <30 mL/min, Child-Pugh B, or a potent CYP3A4 inhibitor[42]Better QoL + efficacy vs. tolterodine in head-to-head; widely used[7]
DarifenacinM3-selectiveLowerStart 7.5 mg daily; increase to 15 mg if needed, but do not exceed 7.5 mg with Child-Pugh B or a potent CYP3A4 inhibitor[37]M3 selectivity in theory reduces CNS side effects
Trospium (IR, ER)Non-selectiveMinimal (quaternary amine)IR: 20 mg twice daily; ER: 60 mg once each morning; take both on an empty stomach at least 1 hour before a meal[13][25]Lower BBB penetration; CNS effects remain possible and renal dosing matters[13]

International agents not available in the US include imidafenacin, propiverine, and propantheline.[1][3]

Clinical Efficacy​

Oral anticholinergics versus placebo (Cochrane 2023; 104 trials, 47,106 participants reported in 92 trials)[1]​

OutcomeEffect vs. placebo
Micturition frequency–0.85 episodes / 24 hr (95% CI 0.73–0.98 lower)
Urgency episodes–0.85 episodes / 24 hr (95% CI 0.67–1.03 lower)
Patient-reported cure/improvementRR 1.38 (95% CI 1.15–1.66)
Quality of lifeMD −4.41 (on −100 to 0 scale)
Withdrawal due to AEsRR 1.37 vs. placebo

Class efficacy​

  • Benefit over placebo is real but modest: about 0.85 fewer voids and 0.85 fewer urgency episodes per 24 hours in the 2023 Cochrane review[1]
  • FDA regulatory trials summarized for anticholinergics in women show 53–80% reductions in incontinence episodes and 12–32% reductions in urinary frequency from baseline; these are mostly short-term trial results[2]
  • In placebo arms of FDA regulatory trials summarized for women with urgency incontinence, incontinence episodes fell 30–47% from baseline; the review notes a likely effect of behavioral modification.[2]

Head-to-head comparisons[7][8]​

Solifenacin versus IR tolterodine (solifenacin superior):

  • Quality of life (SMD −0.12)
  • Patient-reported cure or improvement (RR 1.25)[7]
  • Leakage (WMD −0.30)
  • Urgency episodes (WMD −0.43)
  • Less dry mouth than IR tolterodine in the four-trial sensitivity analysis that excluded an ER-tolterodine trial (RR 0.69, 95% CI 0.51–0.94)[7]

Fesoterodine 8 mg versus ER tolterodine: fesoterodine superior for all efficacy endpoints, but higher withdrawal due to adverse events (RR 1.45) and higher dry mouth (RR 1.80) at 12 weeks.[7]

Tolterodine versus oxybutynin: similar efficacy; tolterodine has less dry mouth (RR 0.65) and fewer withdrawals for adverse events (RR 0.52).[7]

Extended-release > immediate-release: similar efficacy, significantly less dry mouth in ER formulations

Dose comparisons​

  • Tolterodine 1/2/4 mg twice daily: similar leakage and micturition efficacy over 2–12 weeks; 2 and 4 mg twice daily caused more dry mouth than 1 mg twice daily.[7]
  • Solifenacin 5 versus 10 mg once daily: 10 mg reduced frequency and urgency more over 4–12 weeks, but caused more dry mouth.[7]

Adverse Effects​

Common anticholinergic burden[1][2]​

AERate / relative risk
Dry mouthMost common; about 25% (trospium, solifenacin, tolterodine) to 44% (oxybutynin); RR 3.50 vs. placebo[14]
ConstipationCommon; about 8-15%; RR 2.03 vs. placebo[14]
Dry eyesFrequent
Blurred visionUp to about 11%; RR 1.58 vs. placebo[14]
Urinary retentionRR 3.52 vs. placebo[1]
Withdrawal due to AEsRR 1.37 vs. placebo[1]

Cognitive impairment and dementia risk​

The most consequential modern controversy in OAB pharmacotherapy:[9][10][11]

French case-control study (4,810 cases, 24,050 controls): OAB anticholinergic use was associated with OR 1.23 for dementia, with a clear dose-response relationship:[9]

Cumulative exposureOR for dementia
1–90 DDDs1.07
91–365 DDDs1.29
>365 DDDs1.48

Agent-specific signal: in the French case-control study above, oxybutynin and solifenacin carried a particularly marked increased risk of dementia, with no increased risk for trospium.[9] A UK nested case-control study (58,769 dementia cases; 225,574 controls aged 55 years or older) found an association for bladder antimuscarinics at >1095 total standardized daily doses within the 1–11 years before diagnosis (adjusted OR 1.65, 95% CI 1.56–1.75, versus nonuse).[31]

  • Trospium: limited brain penetration supports consideration when an antimuscarinic is needed.[13][14]

These epidemiologic dementia associations describe long-term exposure and diagnosis, a different outcome from short-term prospective cognitive testing. In a 26-person crossover trial of adults aged at least 75 years with mild cognitive impairment, neither drug changed five composite cognitive scores from baseline over 21 days. In a secondary analysis, oxybutynin reduced power and continuity of attention versus placebo at 1–2 hours postdose.[32] A systematic review of 18 studies similarly found no cognitive decline with trospium, darifenacin or fesoterodine, while oxybutynin and tolterodine were each linked to decline in about half of the studies examining them; solifenacin was not associated with cognitive decline in the two studies that assessed it directly, though one study linked it to increased dementia risk in patients with diabetes.[33]

Pooled data: A 2025 meta-analysis of eight studies associated OAB anticholinergic use with higher dementia risk versus no drug therapy (RR 1.20, 95% CI 1.09–1.32) and versus mirabegron (RR 1.28, 95% CI 1.03–1.58); heterogeneity was very high, and confounding by indication remains possible.[26] In a Danish nationwide nested case-control analysis of 58,242 new bladder-drug users aged 60–75 years at entry, anticholinergic use was associated with lower dementia incidence than mirabegron use (IRR 0.82, 95% CI 0.74–0.92); a separate general-population analysis found higher incidence versus nonuse (IRR 1.44, 95% CI 1.40–1.48).[44]

2022 SUFU White Paper conclusions[11]​

  • Chronic use (>3 months) likely associated with increased dementia risk
  • Short-term use (<4 weeks) of most agents was considered likely safe for most patients, but SUFU advises avoiding immediate-release oxybutynin because short-term trials found cognitive effects; individual delirium and retention risks remain.
  • Dose–response associations were reported
  • Lower CNS penetration with trospium, darifenacin and fesoterodine is a theoretical advantage[14]
  • Patients should be counseled about the dementia association before long-term initiation
  • Alternatives (β3-agonists, botulinum toxin, neuromodulation) should be considered especially in elderly and cognitively-vulnerable patients

Mechanism​

Anticholinergic blockade of acetylcholine in the brain disrupts cholinergic neurotransmission required for learning and memory. Greater CNS penetration may raise concern for cognitive effects; antimuscarinics have no validated long-term dementia-risk ranking.[3][12][11][14]

However, one propensity-matched cohort study (782 pairs, adults with normal cognition, MCI or dementia) found no significant association with clinically relevant cognitive decline, though dose and duration were unknown and oxybutynin or tolterodine users trended higher (CDR OR 1.65, 95% CI 0.98–2.77).[52]

Contraindications and Precautions​

Contraindications[2][13]​

  • Uncontrolled narrow-angle glaucoma (the 2024 AUA/SUFU guideline advises extreme caution in any narrow-angle glaucoma and coordination with the treating ophthalmologist)[14]
  • Gastric retention / severe GI obstructive disorders
  • Current urinary retention is a labeled contraindication; a history of retention warrants extreme caution.[13][14]

Use with caution​

SituationConsideration
Elevated PVRIncreased risk of urinary retention; consider an alternative or a cautious trial with repeat PVR. There is no accepted cutoff; most pivotal trials excluded PVR 150-200 mL[14]
Significant BPHMay worsen obstructive symptoms; use with α-blocker if chosen
Cardiac arrhythmiaCan exacerbate tachyarrhythmias
GI motility disordersUlcerative colitis, intestinal atony, myasthenia gravis
Solid oral potassium chlorideContraindicated when anticholinergic effects delay gastrointestinal tablet passage; solid tablets can cause ulcerative or stenotic gastrointestinal lesions.[50]
Renal impairmentTrospium IR: 20 mg nightly if CrCl <30 mL/min; ER is not recommended at that clearance. Oxybutynin patch (Oxytrol) and gel (Gelnique) labels give no renal or hepatic dose guidance; the gel label states there is no experience in renal or hepatic impairment. Check each other agent’s label separately[13][25][27][28]
ElderlyHigher risk of cognitive effects, falls, constipation. Trospium IR label: at 75 years or older, the dose may be titrated down to 20 mg once daily according to tolerability[13]
Parkinson's / MS / scleroderma / hypothyroidismConditions affecting motility and cognition

AUA/SUFU guidelines[14]​

  • Discuss potential dementia and cognitive-impairment risk with patients taking or about to be prescribed antimuscarinics .[14]
  • Use with extreme caution in narrow-angle glaucoma, impaired gastric emptying, or history of urinary retention .[14]
  • Consider a PVR to exclude incomplete emptying, especially with voiding or emptying symptoms; obtain one if there is a history of retention or risk of it, and weigh risk and benefit with the patient
  • Assess at 4–8 weeks for efficacy and side effects .[14]
  • Reassess efficacy and side effects after initiation

Clinical Positioning​

Contemporary paradigm​

2024 AUA/SUFU OAB guideline positions pharmacotherapy as:[14]

  • Offer behavioral measures and discuss β3-agonists or antimuscarinics according to symptoms, adverse effects and preferences.
  • A different-class combination can be considered after an inadequate single-drug response.
  • Botulinum toxin, sacral neuromodulation and PTNS need not await completion of a fixed medication ladder; the guideline permits their selection without prior drug trials through shared decision-making.

EAU 2026 (non-neurogenic female LUTS) offers anticholinergics to women with OAB who fail conservative management and advises shared decision-making, extended-release formulations whenever possible, early review of efficacy and adverse effects, and, if a drug fails, dose escalation, a different formulation or a β3 agonist alone or combined (all Strong). Immediate-release products allow flexible or on-demand dosing but cause more adverse events. EAU finds no anticholinergic clearly superior for cure or improvement and reports that most patients stop within three months. For older women it advises caution with long-term use, especially with existing or risk of cognitive dysfunction, and assessment of anticholinergic burden . In older women, the cognitive impact of anticholinergic drugs increases with length of exposure (level 2); oxybutynin may worsen cognition (level 2), while darifenacin, fesoterodine, solifenacin and trospium have not been shown to cause cognitive dysfunction in short-term studies (level 1b).[30]

When to choose antimuscarinic over β3-agonist​

  • Patient has tried β3-agonist without adequate response
  • Combination therapy: synergistic effect in patients with suboptimal monotherapy
  • Patient preference / cost (antimuscarinics are generic and cheaper)
  • Specific subpopulations where antimuscarinic evidence is stronger (NLUTD, pediatric)

When to avoid anticholinergics​

  • Elderly patient with cognitive concerns: use β3-agonist or trospium
  • Active cognitive impairment or dementia: avoid where an alternative exists
  • BPH with elevated PVR: assess emptying and discuss the potential for worsening retention before an antimuscarinic trial.[14]
  • Narrow-angle glaucoma: antimuscarinics are contraindicated when uncontrolled; use extreme caution when treated.[13][14]

Adherence​

Long-term adherence is suboptimal; across three observational prescription-claims studies reporting both drug classes, 1-year persistence ranged 12–25% for antimuscarinics versus 32–38% for mirabegron.[14][34] Drivers of discontinuation: dry mouth, constipation, cognitive side effects, inadequate efficacy.

Combination Therapy​

Antimuscarinic plus β3-agonist (for example, solifenacin 5 mg with mirabegron 25–50 mg) can improve symptoms after an inadequate single-drug response.[35][14] In SYNERGY, solifenacin 5 mg plus mirabegron 50 mg improved micturition frequency (nominal P values), but the co-primary incontinence comparison versus mirabegron 50 mg did not reach statistical significance; a prespecified age subgroup analysis of 12-month SYNERGY II reported generally greater improvements in incontinence episodes and micturitions with that combination than with either monotherapy.[38][39] In BESIDE, among patients still incontinent after a 4-week solifenacin 5 mg run-in, combination treatment was superior to solifenacin 5 mg for mean daily incontinence episodes, noninferior to solifenacin 10 mg for incontinence episodes in a 3-day diary (a key secondary endpoint), and superior to 10 mg for daily micturitions after 12 weeks.[15][16][35] The AUA/SUFU 2024 guideline offers different-class combination after inadequate single-drug response [14]; over 12 months in SYNERGY II, treatment-emergent adverse events occurred in 49% with mirabegron 50 mg plus solifenacin 5 mg, 41% with mirabegron 50 mg, and 44% with solifenacin 5 mg.[51]

  • Additional frequency reduction over monotherapy
  • Additional urgency or incontinence reduction
  • Increased anticholinergic side effects versus β3-agonist alone

Special Populations​

Neurogenic Lower Urinary Tract Dysfunction (NLUTD)​

Antimuscarinics are a mainstay of pharmacotherapy for bladder storage dysfunction in NLUTD. The 2021 AUA/SUFU NLUTD guideline permits antimuscarinics, β3 agonists, or both to improve bladder storage parameters[17][18][19]; the 2026 EAU Neuro-Urology guideline recommends against using β3 agonists to reduce urodynamically proven neurogenic detrusor overactivity .[45] Antimuscarinic storage effects include:

  • Reliably increase maximum cystometric capacity and voided / catheterized volumes
  • Decrease detrusor pressure
  • May improve urgency and incontinence across NLUTD etiologies, including SCI, MS and spina bifida
  • No evidence of superiority of any agent (guideline)
  • May be combined with β3-agonists (after shared decision-making) or α-blockers (Statement 34 covers α-blockers alone for voiding parameters in spontaneous voiders)[17]
  • Intravesical oxybutynin: has been described for selected CIC-dependent NLUTD patients who cannot tolerate oral treatment.[17]

Pediatric neurogenic bladder​

Oxybutynin is the most-used agent, effective at increasing capacity, lowering storage pressures, abolishing overactive contractions. Mirabegron and (rarely) gabapentin are alternatives in intolerant patients.[20]

Men with BPH​

Antimuscarinics benefit men with predominantly storage symptoms and coexisting BPH, alone or combined with an α-blocker; the AUA/SUFU 2024 guideline supports antimuscarinic or β3 monotherapy, or α-blocker plus either class .[14] Antimuscarinics may raise PVR slightly but have not been associated with significantly more retention in men with BPH-related obstruction, although effects with a PVR above 200 mL are not well studied.[14] Combination with an α-blocker improves OAB symptoms more than α-blocker alone. Check PVR before initiation and at follow-up. The AUA BPH guideline (2026) likewise allows an antimuscarinic alone or with an α-blocker for moderate-to-severe predominant storage LUTS , and adds behavioral measures when storage symptoms persist on medication.[14][21][22][29]

Formulations​

FormulationAdvantagesNotes
Extended-release oralLess dry mouth than IR; QD dosingDefault for most agents
Immediate-release oralFaster onset; cheapestHigher dry mouth burden
Transdermal patch (oxybutynin)Bypasses first-pass metabolism; less dry mouthSkin reactions in some patients
Topical gel (oxybutynin)Application flexibilityTransfer risk to partner / children
Intravesical instillation (oxybutynin)Fewer systemic adverse effects than oral dosing were reported in small NLUTD studies[17]Selected NLUTD / CIC patients with systemic intolerance

Progression to Advanced Therapies​

With inadequate response, intolerance or preference for a procedure, discuss minimally invasive therapies. Under the 2024 AUA/SUFU guideline, medication failure is not required in every case before minimally invasive therapy .[14][23] After an appropriate response to a minimally invasive procedure, discontinue oral OAB medication and restart pharmacotherapy if efficacy wanes .[14]

  • Intradetrusor onabotulinumtoxinA: FDA-labeled doses after inadequate response to or intolerance of an anticholinergic are 100 U for adult OAB and 200 U for adult urinary incontinence due to neurologic detrusor overactivity.[46][17] For idiopathic OAB, measure PVR before injection and counsel about incomplete emptying and possible clean intermittent catheterization.[14]
  • Sacral neuromodulation (InterStim, Axonics)
  • Tibial nerve stimulation: percutaneous PTNS or implantable eCoin and Revi systems.[14][47][48] Revi treats urgency incontinence and is contraindicated during pregnancy and in men with BPH or other lower urinary tract obstruction.[48]

See Also​

References​

1. Stoniute A, Madhuvrata P, Still M, et al. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023;5:CD003781. doi:10.1002/14651858.CD003781.pub3

2. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592–1604. doi:10.1001/jama.2017.12137

3. Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018;189:130–148. doi:10.1016/j.pharmthera.2018.04.010

4. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147 Suppl 2:S80–7. doi:10.1038/sj.bjp.0706560

5. Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248–57. doi:10.1056/NEJMcp1106637

6. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men. JAMA. 2025;334(9):809–821. doi:10.1001/jama.2025.7045

7. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429. doi:10.1002/14651858.CD005429.pub2

8. Nazir J, Kelleher C, Aballéa S, et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: a systematic literature review and network meta-analysis. Neurourol Urodyn. 2018;37(3):986–996. doi:10.1002/nau.23413

9. Malcher MF, Droupy S, Berr C, et al. Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the French National Medical-Administrative Database. J Urol. 2022;208(4):863–871. doi:10.1097/JU.0000000000002804

10. Chancellor MB, Lucioni A, Staskin D. Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment. Urology. 2024;186:123–129. doi:10.1016/j.urology.2023.11.033

11. Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928–1933. doi:10.1002/nau.25037

12. Taylor-Rowan M, Alharthi AA, Noel-Storr AH, et al. Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults. Cochrane Database Syst Rev. 2023;12:CD015405. doi:10.1002/14651858.CD015405.pub2

13. Glenmark Pharmaceuticals. Trospium chloride immediate-release prescribing information. DailyMed. Updated December 30, 2025; accessed September 11, 2026.

14. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11–20. doi:10.1097/JU.0000000000003985

15. Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–333. doi:10.1016/j.eururo.2018.03.020

16. Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025. doi:10.1007/s00228-025-03855-1

17. Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

18. Hamouda A, Covarrubias C, Campeau L. Advancing personalized care for neurogenic bladder — what medical management should be first line for bladder storage symptoms in NLUTD: pro anticholinergic. Neurourol Urodyn. 2025. doi:10.1002/nau.70177

19. Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016;263(12):2555–2564. doi:10.1007/s00415-016-8212-2

20. Diamond DA, Chan IHY, Holland AJA, et al. Advances in paediatric urology. Lancet. 2017;390(10099):1061–1071. doi:10.1016/S0140-6736(17)32282-1

21. Pang R, Zhou XY, Wang X, et al. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. Cochrane Database Syst Rev. 2021;2:CD012336. doi:10.1002/14651858.CD012336.pub2

22. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2023. J Urol. 2024;211(1):11–19. doi:10.1097/JU.0000000000003698

23. Jiang YH, Kuo HC. Current optimal pharmacologic therapies for overactive bladder. Expert Opin Pharmacother. 2023;24(18):2005–2019. doi:10.1080/14656566.2023.2264183

24. Allergan. Oxytrol prescribing information. 3.9 mg/day delivery with twice-weekly patch changes. Accessed September 11, 2026.

25. Trospium chloride extended-release prescribing information. DailyMed. Accessed September 11, 2026.

26. Kotochinsky M, Mora L, Carrazzoni Godoi D, et al. Risk of dementia in patients treated with anticholinergics for overactive bladder syndrome: a systematic review and meta-analysis. Neurol Sci. 2025;46(12):6217-6226. doi:10.1007/s10072-025-08546-4

27. Allergan. OXYTROL (oxybutynin transdermal system) US prescribing information. DailyMed. Accessed September 24, 2026.

28. GELNIQUE (oxybutynin chloride) gel US prescribing information. DailyMed. Accessed September 24, 2026.

29. Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline (2026). Part II: Medical management. J Urol. 2026;216(2):152-160. doi:10.1097/JU.0000000000005098

30. European Association of Urology. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms (LUTS) (Limited Update March 2026). Guideline.

31. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677

32. Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74-81. doi:10.1016/j.eururo.2013.01.002

33. Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021;32(10):2693-2702. doi:10.1007/s00192-021-04909-5

34. Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. "Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review." BMJ Open. 2018;8(11):e021889. doi:10.1136/bmjopen-2018-021889

35. Drake MJ, Chapple C, Esen AA, et al. "Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE)." Eur Urol. 2016;70(1):136-145. doi:10.1016/j.eururo.2016.02.030

36. DailyMed. "Tolterodine tartrate extended-release capsules: prescribing information." US label.

37. DailyMed. "ENABLEX (darifenacin) extended-release tablets: prescribing information." US label.

38. Herschorn S, et al. "Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)." BJU Int. 2017;120(4):562-575. doi:10.1111/bju.13882

39. Mueller ER, et al. "Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study." Neurourol Urodyn. 2019;38(2):779-792. doi:10.1002/nau.23919

40. Russo E, Caretto M, Giannini A, et al. "Management of urinary incontinence in postmenopausal women: An EMAS clinical guide." Maturitas. 2021;143:223–230. doi:10.1016/j.maturitas.2020.09.005

41. DailyMed. "Fesoterodine fumarate extended-release tablets: US prescribing information." US label.

42. DailyMed. "Solifenacin succinate tablets: US prescribing information." US label.

43. DailyMed. "Tolterodine tartrate immediate-release tablets: US prescribing information." US label.

44. Pourhadi N, Janbek J, Gasse C, et al. "Bladder drugs and risk of dementia: Danish nationwide active comparator study." BMJ Med. 2025;4(1):e001125. doi:10.1136/bmjmed-2024-001125

45. European Association of Urology. EAU Guidelines on Neuro-Urology. 2026. Guideline.

46. DailyMed. "BOTOX (onabotulinumtoxinA): US prescribing information." US label.

47. US Food and Drug Administration. "eCoin Peripheral Neurostimulator – P200036." Device approval.

48. US Food and Drug Administration. "Revi System: De Novo summary, DEN220073." Decision summary.

49. Callegari E, Malhotra B, Bungay PJ, et al. "A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder." Br J Clin Pharmacol. 2011;72(2):235–246. doi:10.1111/j.1365-2125.2011.03961.x

50. DailyMed. "Potassium chloride extended-release tablets: US prescribing information." US label.

51. Gratzke C, van Maanen R, Chapple C, et al. "Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)." Eur Urol. 2018;74(4):501–509. doi:10.1016/j.eururo.2018.05.005

52. Welk B, McClure JA. "The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia." Eur Urol Open Sci. 2022;46:22–29. doi:10.1016/j.euros.2022.10.008